| Followers | 0 |
| Posts | 2177 |
| Boards Moderated | 0 |
| Alias Born | 04/13/2018 |
Sunday, September 06, 2020 2:01:51 PM
Important Notes To Keep In Mind:
1. The EU and UK are absolutely independent of the FDA. The pandemic is being handled very differently in Europe. Countries that faced harsh onslaughts like Spain and Italy will be very vocal about getting anything that works to the front lines.
2. The FDA has demonstrated that moves at a snails pace and is effected by political considerations. The fact that the FDA gave the nod to plasma while acknowledging they haven't gotten to our EUA yet is great evidence. I have come to the conclusion that due to the push for plasma the FDA now needs to hedge that move with something to avoid further push back. We have seen the blow back in the news from the vaccine being pushed too soon without science.
3. HIV BLA is going to happen. Easy fixes to the self injecting device, or simply just selling vials. There are plenty of companies that my syringes and plenty of people buy those medical supplies already. Case in point diabetics are already doing this, it does not disrupt their care.
4. We have approvals coming within 6 months, interim severe results, and enough cash and shares on hand to carry us well into October of next year.
1. The EU and UK are absolutely independent of the FDA. The pandemic is being handled very differently in Europe. Countries that faced harsh onslaughts like Spain and Italy will be very vocal about getting anything that works to the front lines.
2. The FDA has demonstrated that moves at a snails pace and is effected by political considerations. The fact that the FDA gave the nod to plasma while acknowledging they haven't gotten to our EUA yet is great evidence. I have come to the conclusion that due to the push for plasma the FDA now needs to hedge that move with something to avoid further push back. We have seen the blow back in the news from the vaccine being pushed too soon without science.
3. HIV BLA is going to happen. Easy fixes to the self injecting device, or simply just selling vials. There are plenty of companies that my syringes and plenty of people buy those medical supplies already. Case in point diabetics are already doing this, it does not disrupt their care.
4. We have approvals coming within 6 months, interim severe results, and enough cash and shares on hand to carry us well into October of next year.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
